Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

The direct and indirect cost burden of Crohn's disease and ulcerative colitis.

Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R.

J Occup Environ Med. 2008 Nov;50(11):1261-72. doi: 10.1097/JOM.0b013e318181b8ca.

PMID:
19001952
2.

Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.

Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

J Med Econ. 2015 Jun;18(6):447-56. doi: 10.3111/13696998.2015.1021353. Epub 2015 Mar 27.

PMID:
25728698
3.

Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.

van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Romberg-Camps MJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B; COIN study group and the Dutch Initiative on Crohn and Colitis.

Gut. 2014 Jan;63(1):72-9. doi: 10.1136/gutjnl-2012-303376. Epub 2012 Nov 7.

PMID:
23135759
4.

Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics.

Mandel MD, Bálint A, Lovász BD, Gulácsi L, Strbák B, Golovics PA, Farkas K, Kürti Z, Szilágyi BK, Mohás A, Molnár T, Lakatos PL.

Eur J Health Econ. 2014 May;15 Suppl 1:S121-8. doi: 10.1007/s10198-014-0603-7. Epub 2014 May 16. Erratum in: Eur J Health Econ. 2014 May;15 Suppl 1;S129. Michael, Mandel D [corrected to Mandel, Michael D].

PMID:
24832845
5.

Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital.

Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF.

Am J Gastroenterol. 2000 Mar;95(3):677-83.

PMID:
10710056
6.

Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey.

Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Lofland JH.

Dig Dis Sci. 2012 Dec;57(12):3080-91. doi: 10.1007/s10620-012-2289-y. Epub 2012 Jul 12.

PMID:
22790905
7.

Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.

Holko P, Kawalec P, Mossakowska M, Pilc A.

PLoS One. 2016 Dec 16;11(12):e0168586. doi: 10.1371/journal.pone.0168586. eCollection 2016.

8.

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults.

Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA.

Gastroenterology. 2008 Dec;135(6):1907-13. doi: 10.1053/j.gastro.2008.09.012. Epub 2008 Sep 17.

10.

Direct and indirect costs to employers of patients with systemic lupus erythematosus with and without nephritis.

Carls G, Li T, Panopalis P, Wang S, Mell AG, Gibson TB, Goetzel RZ.

J Occup Environ Med. 2009 Jan;51(1):66-79. doi: 10.1097/JOM.0b013e31818a405a.

PMID:
19136875
11.

Costs of asthma among US working adults.

Shenolikar R, Song X, Anderson JA, Chu BC, Cantrell CR.

Am J Manag Care. 2011 Jun;17(6):409-16.

12.

Economic burden of systemic lupus erythematosus flares and comorbidities in a commercially insured population in the United States.

Narayanan S, Wilson K, Ogelsby A, Juneau P, Durden E.

J Occup Environ Med. 2013 Nov;55(11):1262-70. doi: 10.1097/JOM.0000000000000008.

PMID:
24202242
13.

Burden of venous leg ulcers in the United States.

Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

J Med Econ. 2014 May;17(5):347-56. doi: 10.3111/13696998.2014.903258. Epub 2014 Mar 24.

PMID:
24625244
14.

Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis.

Odes S, Vardi H, Friger M, Esser D, Wolters F, Moum B, Waters H, Elkjaer M, Bernklev T, Tsianos E, O'Morain C, Stockbrügger R, Munkholm P, Langholz E.

Aliment Pharmacol Ther. 2010 Apr;31(7):735-44. doi: 10.1111/j.1365-2036.2009.04228.x. Epub 2009 Dec 29.

15.

Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.

Rubin DT, Mody R, Davis KL, Wang CC.

Aliment Pharmacol Ther. 2014 May;39(10):1143-55. doi: 10.1111/apt.12727. Epub 2014 Apr 3.

16.

The direct and indirect costs of untreated insomnia in adults in the United States.

Ozminkowski RJ, Wang S, Walsh JK.

Sleep. 2007 Mar;30(3):263-73.

PMID:
17425222
17.

Health care expenditures in ulcerative colitis: the perspective of a self-insured employer.

Hillson E, Dybicz S, Waters HC, Stuart B, Schaneman J, Dabbous O, Erwin WG, Kersh A, Broussard D.

J Occup Environ Med. 2008 Aug;50(8):969-77. doi: 10.1097/JOM.0b013e31816fd663.

PMID:
18695456
18.

Indirect costs associated with metastatic breast cancer.

Wan Y, Gao X, Mehta S, Wang Z, Faria C, Schwartzberg L.

J Med Econ. 2013 Oct;16(10):1169-78. doi: 10.3111/13696998.2013.826228. Epub 2013 Aug 19.

PMID:
23866016
19.

Does anti-TNF therapy cost so many COINs?

Roblin X, Danese S, Peyrin-Biroulet L.

Gastroenterology. 2014 Jan;146(1):309-11. doi: 10.1053/j.gastro.2013.11.012. Epub 2013 Nov 21. No abstract available.

PMID:
24269567
20.

Out-of-pocket Cost Burden in Pediatric Inflammatory Bowel Disease: A Cross-sectional Cohort Analysis.

Sin AT, Damman JL, Ziring DA, Gleghorn EE, Garcia-Careaga MG, Gugig RR, Hunter AK, Burgis JC, Bass DM, Park KT.

Inflamm Bowel Dis. 2015 Jun;21(6):1368-77. doi: 10.1097/MIB.0000000000000374.

Supplemental Content

Support Center